HedgePath Pharmaceuticals, Inc. Announces Management Changes
November 28, 2016 at 05:12 pm EST
Share
On November 22, 2016, HedgePath Pharmaceuticals, Inc. entered into Amendment No. 1 to Second Amended and Restated Supply and License Agreement with Mayne Pharma Ventures Pty Ltd., the current majority stockholder of the company. On November 22, 2016, pursuant to that certain Amended and Restated Equity Holders Agreement, the company removing Frank E. O’Donnell, Jr, M.D. as Executive Chairman of the Board of Directors and as a director of the company and electing E. Brendan Magrab as Chairman of the Board of Directors and as a director of the company. Since March 2013, Mr. Magrab has served as the President and CEO of Transpharmative Advisors, LLC. Mr. Magrab has more than 20 years of experience in pharmaceutical development and marketing, including formulation development, clinical development, regulatory affairs, government affairs, marketing, managed care, legal and patents. Previously, from June 2012 to February 2013, he served as the President and CEO of URL Pharma. From October 2004 to June 2012, he held various positions of increasing responsibility at URL Pharma, including General Counsel and Executive Vice President of Commercial Operations. Prior to joining URL Pharma, from August 2000 to September 2004, Mr. Magrab served as Vice President of Intellectual Property at Alpharma, Inc.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.
INHIBITOR THERAPEUTICS, INC. 